Sponsor
Audience-funded nonprofit news
radio tower icon laist logo
Next Up:
0:00
0:00
Subscribe
  • Listen Now Playing Listen
AirTalk

Zocor, Lipitor, Pravachol and Mevacor: Probing the effectiveness of statins

Information regarding Lipitor, know as Atorvastatin in the pharmaceutical world, is seen in Mosby's 'Nursing Drug Reference' book October 12, 2005 in Des Plaines, Illinois. The manufacturer of Lipitor, Pfizer, will appeal any possible Lipitor patent rulings regarding generic manufacturing of the company's cholesterol drug.
Information regarding Lipitor, know as Atorvastatin in the pharmaceutical world, is seen in Mosby's 'Nursing Drug Reference' book October 12, 2005 in Des Plaines, Illinois. The manufacturer of Lipitor, Pfizer, will appeal any possible Lipitor patent rulings regarding generic manufacturing of the company's cholesterol drug.
(
Tim Boyle/Getty Images
)
Listen 17:25
Zocor, Lipitor, Pravachol and Mevacor: Probing the effectiveness of statins
In 2009, pharmacists filled over 200 million prescriptions for statins, the drug that’s thought to prevent heart attacks and strokes. And, manufacturers of the drug, more commonly known as Zocor, Lipitor, Pravachol and Mevacor, take in $26.2 billion a year from the pills’ sales. Though these medications are hugely popular, their effectiveness has come under tough scrutiny. Researchers question how safe statins really are and recent studies show that users of statins might not get the results they’re promised – indicating that drug companies are neglecting research, and pushing for doctors to recommend the drug in order to boost sales. How much are patients benefiting from taking the cholesterol-reducing medication? Are statins vastly overprescribed?

In 2009, pharmacists filled over 200 million prescriptions for statins, the drug that’s thought to prevent heart attacks and strokes. And, manufacturers of the drug, more commonly known as Zocor, Lipitor, Pravachol and Mevacor, take in $26.2 billion a year from the pills’ sales. Though these medications are hugely popular, their effectiveness has come under tough scrutiny. Researchers question how safe statins really are and recent studies show that users of statins might not get the results they’re promised – indicating that drug companies are neglecting research, and pushing for doctors to recommend the drug in order to boost sales. How much are patients benefiting from taking the cholesterol-reducing medication? Are statins vastly overprescribed?

Guest:

Dr. Sanjay Kaul, MD on the FDA panel about statins, wrote about statins for Journal of the American Medical Association, a cardiologist at the Cedars Sinai Heart Institute.